Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819355 | 0.83 | ELANE (0.49) | ELANECYP2C9CYP1A2CYP3A4 | |
| SCHEMBL17819341 | 0.81 | ELANE (0.42) | ELANECYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17819313 | 0.75 | ELANE (0.39) | ELANECYP2C9CTSK | |
| SCHEMBL17819298 | 0.74 | ELANE (0.46) | ELANECYP2C9CYP1A2CYP3A4CTSK | |
| SCHEMBL17819362 | 0.74 | ELANE (0.49) | ELANECYP2C9CYP1A2CYP3A4CTSK | |
| SCHEMBL17819333 | 0.74 | ELANE (0.61) | ELANECYP2C9CYP1A2CYP3A4CTSK | |
| SCHEMBL20751793 | 0.74 | ELANE (0.48) | ELANECYP2C9CYP1A2CYP3A4 | |
| SCHEMBL17819366 | 0.73 | ELANE (0.47) | ELANECYP2C19 | |
| SCHEMBL19639791 | 0.72 | ELANE (0.46) | ELANECYP2C9CYP1A2CYP3A4CTSK | |
| SCHEMBL20751797 | 0.69 | ELANE (0.40) | ELANECYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| US-9409870-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-9409870-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| WO-2016096638-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168101-A1 | NOVEL COMPOUNDS | ELANE, SERPINB1, MPO | ELANE 1/4885CYP2C9 2366/4885CYP1A2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.